Our focus is innovative and high-quality vaccine for human use. We are dedicated to applying our expertise from antigen discovery, antigen expression, purification and formulation to pre-clinical evaluation, production process development and assay development.
Our team works with cutting-edge equipment and lab resources for microbiology, molecular cell biology, immunology and biochemistry. We also maintain top-notch animal research facilities.
Up to now, CanSinoBIO's R&D team has nurtured a strong pipeline over the years. We have an impressive array of vaccine candidates currently undergoing clinical studies, including TB vaccines, PBPV, PCV13i and DTcP, etc. In addition, we have six vaccine candidates remain in the pre-clinical development stage.
Based on the recombinant technology, we have engineered a number of vaccine-producing bacterial strains which allow us to accomplish exceptionally high vaccine yields while simplifying overall manufacturing processes.